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PLERIXAFOR USE IN AUTOLOGOUS HEMATOPOIETIC CELL TRANSPLANT
CANDIDATES AT HIGH RISK FOR MOBILIZATION FAILURE
Shapiro, J.1, Perkins, J.2, Bookout, R.1, Ayala, E.2, Fernandez, H.2,
Janssen, W.2, Anasetti, C.2 1H. Lee Moffitt Cancer Center, Tampa,
FL; 2H. Lee Moffitt Cancer Center, Tampa, FL
Practice guidelines were developed at our institution to optimize
CD34 cell mobilization for autologous hematopoietic cell transplant.
We defined patients (pts) at high risk for mobilization failure and eli-
gible to receive G-CSF and plerixafor if they met any of the following
criteria: 1) received3ormore lines of prior chemotherapy; 2) received2
ormore lines of prior chemotherapy plus a radioimmunoconjugate; 3)
received 2 or more lines of prior chemotherapy plus radiation therapy
(XRT) to extensive fields; 4) received 4 ormore cycles of hyper-CVAD
or4ormore cycles of lenalidomide; or 5) hypocellular bonemarrow (\
25% cellularity). From 1/09-11/09, 30 consecutive high-risk pts re-
ceived G-CSF and plerixafor as primary mobilization therapy. All pts
received 4 doses of G-CSF (10 mcg/kg/d) and on the evening of the
4thday (at approximately7pm), they receivedG-CSF followedbypler-
ixafor 0.24 mg/kg. 6 pts were dosed at 0.16 mg/kg due to reduced cre-
atinine clearance. Apheresiswas started themorning after the first dose
of plerixafor. G-CSF, plerixafor, and apheresis were continued until at
least 2 or 4  10E6 CD341 cells/kg were collected, depending on
whether a single or a tandem transplant was planned. The median
age of the patients was 62 (range 33-71) years. Diagnoses includemul-
tiple myeloma (22), non-Hodgkin’s lymphoma (7) andHodgkin’s dis-
ease (1). Pts met the following high risk criteria: 3 or more lines of
chemotherapy (9 pts); 2 or more lines of chemotherapy plus XRT (2
pts); 4 ormore cycles of hyper-CVAD(4 pts); 4 ormore cycles of leno-
lidomide (18 pts); hypocellular bone marrow (6 pts). 7 pts had more
than 1 high risk feature. The median number (range) of G-CSF doses
were 4 (4-7), plerixafor doses 1 (1-3) and aphereses, 1 (1-3). The num-
ber of pts collectingat least 210E6CD341 cells (cumulative)with1,
2, and3 aphereseswere 23 (77%), 26 (87%), and28 (93%).Themedian
(range)of the numberofCD341 cells/kg collectedwith1 apheresis for
all pts was 4.23 (0.1-24.82). 4 pts were not transplanted: 2 due to an in-
ability to collect and 2 for other reasons. Of those 26 pts transplanted,
themedian time to absolute neutrophil count. 500/uLwas 12 (range
10-13) days andplatelet count. 20,000/uL (untransfused)was 17days
(range10-42)post-transplant.Weconclude thatplerixafor isbeneficial
in pts who are at high risk formobilization failure with 93%of patients
mobilizing adequate numbers of CD341 cells for transplant.145
EOSINOPHILIA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION:
ANALYSIS OF FREQUENCY AND PROGNOSIS
Miyazaki, Y.1, Nawa, Y.2, Kohashi, S.2, Nakase, K.2, Hara, M.2 1Ehime
University Graduate School of Medicine, Toon, Ehime, Japan; 2Ehime
Prefectural Central Hospital, Matsuyama, Ehime, Japan
Introduction: The patients with eosinophilia after allogeneic stem
cell transplantation (allo-SCT) have often been reported to have
much longer overall survival and progression free survival than with-Table 1.
Diagnosis Previous Chemo
Plerixa
Dose
1 MM CTD , VELCADE 0.24 MG
2 NHL ABVD 0.24 MG
3 MM RDC, REVLIMID 0.24 MG
4 MM CTD, VELCADE 0.24 MG
5 HD ABVD, RADIOTHERAPY, ICE 0.24 MG
6 NEUROBLASTOMA TEMOZOLIDE, MIBG (RADIO
IODINATED TREATMENT
0.24 MG
7 MM CTD 0.24 MG
8 MM VELCADE + DEXAMETHASONE, REVLIMID 0.24 MG
9 HD ABVD, GEM-P 0.24 MG
10 MM CTD, VELCADE 0.24 MG
11 MM CTD, DEXAMETHASONE, RADIOTHERAPY 0.24 MGout eosinophilia. However, eosinophilia after autologous stem cell
transplantation (auto-SCT) has not been reported well. In this study,
we retrospectively analyzed the frequency of eosinophilia and the
prognosis of patients with eosinophilia after auto-SCT.
Patients andMethods: Between January 2006 andDecember 2009,
35 patients (18 multiple myeloma and 17 nonHodgkin’s lymphoma)
experienced autologous peripheral blood stem cell transplantation at
the Ehime Prefectural Central Hospital were analyzed. Eosinophilia
was defined according to the following criteria: (1) The count of
eosinocyte in the peripheral blood was over 500 cells per micro liter
after transplantation, (2) There was little relation to the drug-related
allergic reaction.
Results: The median observation time was 480 days (39-1497).
Fourteen of 35 patients (40%) had eosinophilia. The median onset
time was day 39.5 (range, day 22-116) and the duration of eosino-
philia was less than one month in most cases. On univariate analysis
between the group with eosinophilia and without eosinophilia, there
were no significant differences regarding age (p 5 0.625), time to
engraftment (p 5 0.448), sex (p 5 0.888) and CD341 cell dose
(p5 0.987). Kaplan-Meier method demonstrated that 2-year overall
survival and 2-year progression free survival were similar between
two groups (70.7% vs 48.8%; p 5 0.879, 51.6% vs 25.1%; p 5
0.569, respectively).
Conclusions: The frequency of eosinophilia after auto-SCT is
unexpectedly high. However, the duration of eosinophilia after
auto-SCT is much shorter than after allo-SCT and the relationship
between prognosis and eosinophilia may be little.146
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Vieira, S., Monroe, D. The Trustees of London Clinic, London, United
Kingdom
Introduction: Plerixafor (MOZOBIL) is an antagonist of alpha-
chemokine receptor CXCR and one of the new additions to the
Haematology discipline, it is a haematopoietic stem cell mobilizer.
Plerixafor is indicated in combination with Granulocyte Colony
Sitimulating Factor (GCSF) for Peripheral Blood Stem Cell
(PBSC) collections in Multiple Myeloma (MM) and Lymphoma
patient group with a poor mobilisation history.
Method: At The London Clinic, 12 patients received Plerixafor for
PBSC colection between May 2009 and September 2010. All patients
met the criteria prior to treatment (WhiteBloodCount. 2.5 109/L,
Absolute Neutrophil Count . 1.5  109/L, Platelet . 85  109/L,
Serum Creatinine \1.5 mg/dL, Aspartate transaminase (AST),
Alanine Transaminase (ALT), Bilirubin\2ULNwith no evidence
of Hepatitis B and C. Patient demographic data is shown in Table 1.
Two patients had an underlying documentedmedical problem (corto-
chondritis and glaucoma).
Results: Nine of the patients were diagnosed with MM, one with
Non-Hodgkin’s Lymphoma (NHL), one with Hodgkin’s Disease
and one with Neuroblastoma. All patients received four consecutive
days of GCSF 10 mg/kg prior to Plerixafor. Plerixafor was given 10
hours before the PBSC collection and GCSF was repeated in thefor GCSF
Dose
PBSC 1 CD34+
Cells/KG
Recipient Weight
PBSC2 CD34+
Cells/KG
Recipient Weight
PBSC 3 CD34+
Cells/KG
Recipient Weight
/KG 10 m/KG 7.39 X X
/KG 10 m/KG 21.79 X X
/KG 10 m/KG 4.62 X X
/KG 10 m/KG 2.03 X X
/KG 10 m/KG 1.16 1.08 0.42
/KG 10 m/KG 0.47 1.62 0.43
/KG 10 m/KG 2.55 5.48 X
/KG 10 m/KG 15.16 X X
/KG 10 m/KG 21.79 X X
/KG 10 m/KG 1.52 3.74 X
/KG 10 m/KG 0.64 1.50 1.34
S208 Poster Session Imorning on collection one hour prior to the collection time. All
patients received 0.24mg/kg/day of Plerixafor. There were no side
effects observed. Only one of the patients required a second dose
of Plerixafor and five patients had not reach the required CD34
count of 4  106 cells/kg.
Conclusions: Plerixafor was used at The London Clinic recently
with favourable outcomes. The target for all cases was CD341 cells
4  106 cells/kg recipient body weight. Two patients responded ex-
tremely well with a CD341 count of 21.79  106 cells/kg and 15.16
 106 cells/kg achieved. Three patients had a poor outcomes, where
the collection was below 3  106 cells/kg of CD341 count was col-
lected. The other seven patients met the target required of CD341
count of 4  106 cells/kg or above.
According to this study Plerixafor has improved PBSC outcome
with seven patients out of 12 in this study.
Due to the small numbers this study it is thus far inconclusive but
it would be sensible to say Prelixafor made a difference for our 11 pa-
tients. An Ongoing study with new patient experiences is needed.
More than one dose of Plerixafor was required for heavily pre-treated
patients who are historically poor mobiliser of PBSC.147
ANALYSIS OF TOXICITY PROFILE OF CBV VS BEAM IN LYMPHOMA
PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANT – A SINGLE
INSTITUTION RETROSPECTIVE REVIEW
Khalife, M., Neme, K., Janakiraman, N. Henry Ford Hospital, Detroit,
MI
Introduction: Several preparative regimens are used in Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients prior
to autologous hematopoietic stem cell transplant (HSCT). These in-
clude CBV (cylophosphamide, etoposide and carmustine), BEAM
(carmustine, etoposide, cytarabine andmelphalan) or TBI based reg-
imens. This study retrospectively compares the toxicities of CBV vs
BEAM in lymphoma post-HSCT in our institution.
Methods: We retrospectively reviewed the charts of 77 lymphoma
patients who underwent autologous HSCT between 1999 and
2010. 35 patients received CBV between 1999 and 2005 (11 HL
and 24 NHL) and 42 patients received BEAM between 1999 and
2010 (12 HL and 30 NHL). CBV consisted of cyclophosphamide
7200 mg/m2, etoposide 1600 mg/m2, and carmustine 300 mg/m2.
BEAM consisted of carmustine 300 mg/m2, etoposide 1600 mg/
m2, cytarabine 1600 mg/m2, and melphalan 140 mg/m2. Lung toxic-
ity was defined as a 15% drop in adjusted DLCO (carbon monoxide
diffusing capacity) on pulmonary function test (PFT) or respiratory
symptoms requiring steroids within six weeks post-HSCT. Clini-
cally significant lung toxicity was defined as respiratory symptoms
requiring steroids or leading to death.
Results: Lung toxicity occurred in 10/42 (23.8%) of BEAM and
13/35 (37.1%) of CBV patients (p 5 0.203). However, clinically
significant lung toxicity occurred only in 3/42 (7.1%) of BEAM
(one of which was lethal) and only in 1/35 (2.9%) of CBV patients
(p 5 0.621). All 4 clinically significant lung toxicities occurred in
HL. Cardiac toxicities were comparable (11.9% after BEAM vs
8.6% after CBV; p 5 0.722). Time to engraftment defined as
neutrophil . 500 (12.9 days after CBV vs 11.3 days after
BEAM; p 5 0.031), diarrhea (65.7% after CBV vs 31.0% after
BEAM; p 5 0.002) and infections requiring intravenous antibi-
otics (60.0% after CBV vs 14.3% after BEAM; p\ 0.001) were
higher after CBV. Severe mucositis requiring parenteral nutrition
was comparable (21.4% after BEAM and 14.3 after CBV p 5
0.418).
Conclusion: HL patients, especially those who received BEAM,
appear to be at higher risk of clinically significant lung toxicity
compared to NHL patients. Prior bleomycin may have contrib-
uted to this. Most patients who had a 15% decline in DLCO
post HSCT did not experience clinically significant lung toxicity.
Therefore, the value of post HSCT PFT is unclear and close
monitoring of high risk patients for symptoms is warranted.
Finally, the time to engraftment and other toxicities favored
BEAM.148
G-CSF DOSE ESCALATION STARTING DAY 8 AFTER SALVAGE RICE
CHEMOTHERAPY RESULTS IN ADEQUATE AND PREDICTABLE AUTOLO-
GOUS PERIPHERAL BLOOD STEM CELL COLLECTION IN RELAPSED/
REFRACTORY LYMPHOMA
Weber, A.M., Pillai, P., Styler, M.J., Mullaney, R., Topolsky, D.,
Ward, K.M., Crilley, P. Hahnemann University Hospital, Philadelphia,
PA
Introduction: Optimal dosing and timing of G-CSF for stem cell
mobilization after salvage RICE (Rituximab, Ifosfamide, Carbopla-
tin, and Etoposide) for relapsed/refractory lymphoma is unclear.
Common G-CSF regimens have doses ranging from 5-16 mcg/kg/
d starting one to several days after chemotherapy until a predeter-
mined variable is reached to initiate peripheral blood stem cell
collection.
Patients and Methods: We performed a retrospective analysis of
stem cell collection with G-CSF after salvage RICE for consecutive
patients with relapsed/refractory lymphoma at our center. Our earlier
practice was augmenting stem cell mobilization with 16 mcg/kg/
d G-CSF from Day 1 to final day of collection to achieve WBC .
10,000/mm3 prior to initiating stem collection (Standard dose group).
We observed difficulties in terms of adequacy and timing of collection
with this method. We modified the regimen to G-CSF at 5 mcg/kg/
d from Day 1 to 7, followed by dose escalation to 16 mcg/kg/d on
Day 8 until final day of collection, and a planned peripheral blood
stem collection beginning Day 12 (Dose escalation group).
Results: Standard dose group: Three patients (2 DLBCL, 1 Hodg-
kin’s lymphoma) received salvage RICE for 2 to 3 cycles. Peripheral
blood stem cell collection resulted in CD341 yields of only 0.3 to 3.0
x106 per kg in 5 to 6 apheresis sessions initiated between day 11 and
day 16.
Dose escalation group: Four patients (2 DLBCL, 1 T cell rich B
cell lymphoma, 1 Hodgkin’s lymphoma) received salvage RICE for
2 to 4 cycles. Peripheral blood stem cell collection resulted in
more than sufficient CD341 yields (all . 3x106 per kg, range 3.80
to 7.10 x106) in only 1 to 3 apheresis sessions initiated on day 12.
Conclusion: A timed escalation to high dose G-CSF on day 8 sal-
vage RICE chemotherapy for relapsed/refractory lymphoma re-
sulted in superior CD341 cells for collection with fewer apheresis
requirements and a predictable apheresis start day.149
OPTIMIZING THE EFFICACY OF PLERIXAFOR AS A SALVAGE OPTION
IN POOR MOBILIZERS FOLLOWING CHEMOTHERAPY PLUS G-CSF
MOBILIZATION
Kochuparambil, S.T.1, Mebel, E.R.3, DeRemer, D.L.2, Jillella, A.P.1,
Awan, F.T.1 1Medical College of Georgia, Augusta, GA; 2Medical College
of Georgia, Augusta, GA; 3University of PittsburghMedical Center, Pitts-
burgh, PA
Introduction: Recent data of the combination of G-CSF (G) with
Plerixafor (P) has established its efficacy in stem cell mobilization
for autologous transplants. However, there is limited data about
the utility of plerixafor in patients who are beingmobilized with che-
motherapy and G.
Methods: In this study we describe our experience with the use of
plerixafor as a salvage option in 12 patients (6 Non-Hodgkin Lym-
phoma, 3 Multiple Myeloma, 2 Hodgkin Lymphoma, 1 Ewings
Sarcoma) who fail to optimally mobilize CD341 cells (\ 10
CD341 cells/ul at neutrophil recovery) after G. Patients received
Cyclophosphamide (CY) (3-4 g/m2) followed by G (10 mcg/kg)
from D1 to D10. Data was collected on mobilization and transplant
outcomes and analyzed utilizing SPSS version 13.0.
Results: The median age was 60 years (range 18-76). 75% were
males. Patients had received a median of 2 lines of therapy (range
1-3) prior to stem cell mobilization. Following failure to mobilize
with G post CY, at neutrophil recovery patients received a median
of 2.5 doses of P (range 1-8). The average number of apheresis ses-
sions was 4.2 and the total number of CD341 stem cells collected
was 4.0x106/kg. Utilizing a cut-off of 2x106 CD341/kg, one patient
who received P had an unsuccessful harvest. ThreeNHLpatients re-
quired. 4 doses of P, but all eventually collected. 2 106 CD341
